Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Flagstar Bank NA (FLG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Flagstar Bank NA — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.69 (market cap $8.04B), while Flagstar Bank NA trades at $15.18 (market cap $6.24B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Flagstar Bank NA pays a 0.27% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | FLG | |
|---|---|---|
Market Cap | $8.04B | $6.24B |
Sector | Health | Financials |
52-Week High | $339.75 | $15.28 |
52-Week Low | $241.71 | $10.72 |
Enterprise Value | $7.85B | — |
Dividend Yield | — | 0.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Flagstar Bank (FLG) trades at $14.88, down 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows improving fundamentals with two consecutive quarterly EPS beats and a positive Q1 2026 net income of $0.04 per share. Recent news highlights management's focus on technology transformation and balance sheet stabilization, while the P/B ratio of 0.82 indicates potential undervaluation relative to book value.
The outlook is cautiously optimistic with a consensus price target of $17.05 offering 14.6% upside. Risks include negative net income margins and high interest expenses, but analyst sentiment is positive with no sell ratings. The upcoming Q2 2026 earnings report on July 24, 2026, will be critical for confirming the turnaround trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →
